Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Saracatinib - AstraZeneca

Drug Profile

Saracatinib - AstraZeneca

Alternative Names: AZD 0530; Saracatinib difumarate

Latest Information Update: 20 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Baylor College of Medicine; Brigham and Women's Hospital; Loyola University Chicago; NHS National Services Scotland; Sheffield Teaching Hospitals NHS Foundation Trust; Stanford University; University of Cincinnati; University of Miami; University of South Florida; Yale University
  • Class Analgesics; Antidementias; Antineoplastics; Benzodioxoles; Quinazolines; Small molecules
  • Mechanism of Action Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Cancer pain; Lymphangioleiomyomatosis
  • No development reported Alcoholism
  • Discontinued Bone cancer; Breast cancer; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 18 Mar 2019 Saracatinib receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA
  • 12 Sep 2018 AstraZeneca in collaboration with King's College London plans a phase I trial for Parkinson's disease in United Kingdom (NCT03661125)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top